Sugi Predict

Sugi Predict / Compounds / SCHEMBL9976417

SCHEMBL9976417

SCHEMBL9976417

CNCCCC[C@H](NC)C(C)=O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 1/20 0.47
▸ CPB2 Q96IY4 1/20 0.36
▸ FOLH1 Q04609 1/20 0.36
▸ EPHX1 P07099 1/20 0.34
▸ SIRT6 Q8N6T7 1/20 0.34
▸ SIRT1 Q96EB6 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ KDM4A O75164 1/20 0.33
▸ KDM4C Q9H3R0 1/20 0.33
▸ SIRT5 Q9NXA8 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ ALB P02768 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10026152 1.00 KISS1R (0.47) KISS1RCPB2FOLH1EPHX1SIRT6
SCHEMBL14525109 1.00 KISS1R (0.47) KISS1RCPB2FOLH1EPHX1SIRT6
SCHEMBL23946773 0.98 KISS1R (0.46) KISS1RCPB2FOLH1EPHX1SIRT6
SCHEMBL12890790 0.94 KISS1R (0.53) KISS1RCPB2FOLH1EPHX1KDM4E
SCHEMBL14525182 0.94 KISS1R (0.53) KISS1RCPB2FOLH1EPHX1KDM4E
SCHEMBL13366903 0.94 KISS1R (0.53) KISS1RCPB2FOLH1EPHX1KDM4E
SCHEMBL24155383 0.87 KISS1R (0.45) KISS1RCPB2FOLH1SIRT6SIRT1
SCHEMBL24155380 0.87 KISS1R (0.45) KISS1RCPB2FOLH1SIRT6SIRT1
SCHEMBL24155382 0.87 KISS1R (0.45) KISS1RCPB2FOLH1SIRT6SIRT1
SCHEMBL16221913 0.87 KISS1R (0.45) KISS1RCPB2FOLH1SIRT6SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330134-A1 METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION STARPHARMA PTY LTD. (AU) 2023-10-19 — — US disclosed
US-20230330240-A1 TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS BIOHAVEN THERAPEUTICS LTD (US) 2023-10-19 — — US disclosed
EP-4227300-A1 TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Yantai Lannacheng Biotechnology Co., Ltd. (CN) 2023-08-16 — — EP disclosed
WO-2021195401-A1 TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS BIOHAVEN THERAPEUTICS LTD. (US) 2021-09-30 — — WO disclosed
WO-2021102052-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. (US) 2021-05-27 — — WO disclosed
WO-2021056077-A1 THERAPEUTIC DENDRIMER STARPHARMA PTY LTD (AU) 2021-04-01 — — WO disclosed
WO-2021035310-A1 TARGETED DENDRIMER CONJUGATES STARPHARMA PTY LTD (AU) 2021-03-04 — — WO disclosed
US-20210030785-A1 METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION STARPHARMA PTY LTD (AU) 2021-02-04 — — US disclosed
WO-2021003050-A2 CD38-BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2021-01-07 — — WO disclosed
WO-2020132588-A1 COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS KLEO PHARMACEUTICALS, INC. (US) 2020-06-25 — — WO disclosed
WO-2020107078-A1 DENDRIMER FOR THERAPY AND IMAGING STARPHARMA PTY LTD (AU) 2020-06-04 — — WO disclosed
WO-2019193576-A1 NOVEL GLP-1 ANALOGUES SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2019-10-10 — — WO disclosed
WO-2019023501-A1 UNIVERSAL ABT COMPOUNDS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-01-31 — — WO disclosed
WO-2019005966-A1 DENDRIMER DRUG CONJUGATES FOR SUSTAINED INTRA-ARTICULAR DELIVERY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-01-03 — — WO disclosed
WO-2018031690-A1 DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES SEATTLE GENETICS, INC. (US) 2018-02-15 — — WO disclosed
US-20170298097-A1 Peptide Derivatives and Uses Thereof NOSOPHARM (FR) 2017-10-19 — — US disclosed
WO-2016046409-A1 NOVEL PEPTIDE DERIVATIVES AND USES THEREOF NOSOPHARM (FR) 2016-03-31 — — WO disclosed
US-8779191-B2 Methods and compositions for preparing lisdexamfetamine and salts thereof CAMBREX CHARLES CITY, INC. (US) 2014-07-15 — — US disclosed
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2012-07-26 — — US disclosed
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof AVISTA PHARMA SOLUTIONS, INC. 2012-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF PNMT, COMT, DDT KISS1R 826/4885CPB2 3762/4885FOLH1 512/4885
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof SLC6A3, COMT, LPXN KISS1R 560/4885CPB2 4352/4885FOLH1 679/4885
US-20230330134-A1 METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION SARS1, ACE, ACE2 KISS1R 326/4885CPB2 323/4885FOLH1 1069/4885
US-20170298097-A1 Peptide Derivatives and Uses Thereof VIP, IAPP, NGLY1 KISS1R 381/4885CPB2 236/4885FOLH1 138/4885
US-20210030785-A1 METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION NAPA, CX3CR1, KISS1R KISS1R 3/4885CPB2 2071/4885FOLH1 1278/4885
US-20230330240-A1 TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS HAVCR2, ACE2, EPCAM KISS1R 988/4885CPB2 206/4885FOLH1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.